Robert Ryan

Dr. Robert Ryan is currently the CEO of Innova Therapeutics. Dr. Ryan was previously CEO and co-founder of Scioderm, which is a company that developed a topical therapy for the orphan disease, Epidermolysis Bullosa. Scioderm was the first Biotech to receive “Breakthrough Therapy” designation from the FDA. Dr. Ryan led the successful sale of Scioderm to Amicus in September 2015 for approximately $957M, in a period of less than 2.5 years from initiation of the company and a total spend of less than $25M.

​Dr. Ryan has more than 30 years of research/pharmaceutical/biotech experience, spanning the global development process from preclinical through Phase IV in many therapeutic areas including oncology (16+ years), infectious diseases, GI and metabolic diseases, pain, neurology, dermatology, respiratory, cardiovascular). Dr. Ryan previously held senior regulatory positions at PPD, INC Research, and Quintiles, in addition to senior preclinical, program management and clinical positions with Roche, Bristol-Myers Squibb (BMS), Celtic Pharma, UCB, Atherogenics, and Pfizer.